ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1047
0,00%
Bitcoin
66.860,22
-0,33%
Brent Oil
83,76
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. SAB Biotherapeutics Inc (SABS)

  7. SAB Biotherapeutics Inc (SABS) Notícias

SABS

SAB Biotherapeutics (SABS)

SAB Biotherapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SABS
DataHoraFonteTítuloCódigoCompanhia
06/05/202408:15GlobeNewswire Inc.SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of DirectorsNASDAQ:SABSSAB Biotherapeutics Inc
16/04/202408:15GlobeNewswire Inc.SAB Biotherapeutics Provides SAB-142 Trial UpdateNASDAQ:SABSSAB Biotherapeutics Inc
08/04/202408:15GlobeNewswire Inc.SAB Biotherapeutics to Present at INNODIA Annual MeetingNASDAQ:SABSSAB Biotherapeutics Inc
04/04/202408:15GlobeNewswire Inc.SAB Biotherapeutics to Present at the Needham Virtual Healthcare ConferenceNASDAQ:SABSSAB Biotherapeutics Inc
29/03/202408:15GlobeNewswire Inc.SAB Biotherapeutics Reports Full Year 2023 Operating and Financial ResultsNASDAQ:SABSSAB Biotherapeutics Inc
25/03/202411:15GlobeNewswire Inc.SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza TreatmentNASDAQ:SABSSAB Biotherapeutics Inc
08/03/202418:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SABSSAB Biotherapeutics Inc
23/02/202418:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SABSSAB Biotherapeutics Inc
23/02/202410:00GlobeNewswire Inc.SAB Biotherapeutics to Present at the BIO CEO & Investor ConferenceNASDAQ:SABSSAB Biotherapeutics Inc
08/02/202410:00GlobeNewswire Inc.SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:SABSSAB Biotherapeutics Inc
02/02/202409:30GlobeNewswire Inc.SAB Biotherapeutics Announces Executive Leadership ChangeNASDAQ:SABSSAB Biotherapeutics Inc
26/01/202418:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SABSSAB Biotherapeutics Inc
23/01/202419:58GlobeNewswire Inc.SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:SABSSAB Biotherapeutics Inc
02/01/202418:30GlobeNewswire Inc.SAB Biotherapeutics Announces 1-for-10 Reverse Stock SplitNASDAQ:SABSSAB Biotherapeutics Inc
18/12/202311:34Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SABSSAB Biotherapeutics Inc
08/12/202319:26Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SABSSAB Biotherapeutics Inc
29/11/202309:30GlobeNewswire Inc.SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 DiabetesNASDAQ:SABSSAB Biotherapeutics Inc
29/11/202302:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SABSSAB Biotherapeutics Inc
20/11/202318:45Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:SABSSAB Biotherapeutics Inc
20/11/202309:30GlobeNewswire Inc.SAB Biotherapeutics Appoints Katie Ellias to the Board of DirectorsNASDAQ:SABSSAB Biotherapeutics Inc
15/11/202323:10Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:SABSSAB Biotherapeutics Inc
14/11/202309:30GlobeNewswire Inc.SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 DiabetesNASDAQ:SABSSAB Biotherapeutics Inc
14/11/202309:15GlobeNewswire Inc.SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company UpdatesNASDAQ:SABSSAB Biotherapeutics Inc
13/11/202318:48Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SABSSAB Biotherapeutics Inc
09/11/202309:30GlobeNewswire Inc.SAB Biotherapeutics to Present at Piper Sandler Healthcare ConferenceNASDAQ:SABSSAB Biotherapeutics Inc
03/11/202318:00Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SABSSAB Biotherapeutics Inc
03/11/202317:40Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SABSSAB Biotherapeutics Inc
24/10/202308:30GlobeNewswire Inc.SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial OfficerNASDAQ:SABSSAB Biotherapeutics Inc
19/10/202308:30GlobeNewswire Inc.SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 DiabetesNASDAQ:SABSSAB Biotherapeutics Inc
16/10/202317:08Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SABSSAB Biotherapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SABS

Seu Histórico Recente

COIN
VSYSKRW
V SYSTEMS
DBI
IN48
MSCI Fintech Innovation ...
NYSE
CMN
Cantel
COIN
LARIXUST
Larix
BIT
F17566
Vontobel Financial Produ...
BIT
COV
Cover 50
BIT
P1CSN2
BNP Paribas Issuance
BOV
ELETG340
ELETG340 Ex:33,6
BIT
S29092
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados